Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Dow Climbs As Pharma Stocks Jump, but Will Drug M&A Hurt UnitedHealth?

The Dow Jones Industrials (DJINDICES: ^DJI  ) rose more than 40 points Monday as investors continued to ride the wave of enthusiasm that has accompanied the beginning of earnings season. Leading the way higher for the Dow were Pfizer (NYSE: PFE  ) and Merck (NYSE: MRK  ) , which gained 2% and 1.4% respectively. But among the biggest decliners in the Dow Jones Industrials was UnitedHealth Group (NYSE: UNH  ) , whose 1.1% drop raised obvious questions about whether strength in pharma stocks automatically means greater pressure on health-insurance companies.

The big move up for Pfizer came on news that Pfizer had had merger talks with a major British drugmaker that would have created an even larger drug colossus to lead the industry. Even though some analysts question whether a Pfizer merger would even make sense, it does highlight the pressure that Pfizer, Merck, and other drug companies are under to make sure that they can keep their pipelines full and replace lost revenue from treatments that lose their patent protection. Moreover, with companies scrambling to find every possible way to cut costs so as to allow as much revenue as possible to flow down to bottom-line profits, the idea of Pfizer or Merck finding large partners for business combinations makes plenty of sense.

By contrast, UnitedHealth last week reported earnings that were already hurt by health-care reform, and signs of strength from pharmaceutical companies could make things even more difficult for health insurers. UnitedHealth Group in particular has relationships with drugmakers through its Optum pharmacy-benefit management division, and indirectly, UnitedHealth will also bear the added cost of drugs that might result if major combinations of pharmaceutical companies lead to greater pricing power against health insurers.

In theory, UnitedHealth Group has the ability to pass through higher drug costs to its members in the form of higher premiums. Yet with Obamacare's restrictions on medical loss ratios and with competitive pressures to keep insurance premiums down, UnitedHealth might find it more difficult than expected to sustain its profit margins if drug costs rise. Already, many ultra-high-priced medications have forced UnitedHealth Group and its peers to make tough decisions about whether to cover them under conventional insurance, and that controversy is likely to go on for a long time.

In the long run, a stronger pharmaceutical sector could lead to higher drug costs, and that in turn could hurt health insurance companies in their efforts to offer low-cost insurance alternatives while remaining profitable. Investors in drug companies need to understand the political issues that are involved and not take sales gains for granted as discussions of possible future mergers continue.

6 stock picks poised for incredible growth
They said it couldn't be done. But David Gardner has proved them wrong time, and time, and time again with stock returns like 926%, 2,239%, and 4,371%. In fact, just recently one of his favorite stocks became a 100-bagger. And he's ready to do it again. You can uncover his scientific approach to crushing the market and his carefully chosen six picks for ultimate growth instantly, because he's making this premium report free for you today. Click here now for access.

Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2923018, ~/Articles/ArticleHandler.aspx, 8/30/2015 6:24:08 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Dan Caplinger

Dan Caplinger has been a contract writer for the Motley Fool since 2006. As the Fool's Director of Investment Planning, Dan oversees much of the personal-finance and investment-planning content published daily on With a background as an estate-planning attorney and independent financial consultant, Dan's articles are based on more than 20 years of experience from all angles of the financial world.

Today's Market

updated 1 day ago Sponsored by:
DOW 16,643.01 -11.76 -0.07%
S&P 500 1,988.87 1.21 0.06%
NASD 4,828.33 15.62 0.32%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

8/28/2015 4:55 PM
^DJI $16643.01 Down -11.76 -0.07%
MRK $55.37 Up +0.42 +0.76%
Merck & Co., Inc. CAPS Rating: ****
PFE $32.66 Down -0.60 -1.80%
Pfizer CAPS Rating: ****
UNH $117.28 Down -0.49 -0.42%
UnitedHealth Group CAPS Rating: *****